1. Home
  2. ELME vs BEAM Comparison

ELME vs BEAM Comparison

Compare ELME & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELME
  • BEAM
  • Stock Information
  • Founded
  • ELME 1960
  • BEAM 2017
  • Country
  • ELME United States
  • BEAM United States
  • Employees
  • ELME N/A
  • BEAM N/A
  • Industry
  • ELME Real Estate Investment Trusts
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ELME Real Estate
  • BEAM Health Care
  • Exchange
  • ELME Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • ELME 1.4B
  • BEAM 1.7B
  • IPO Year
  • ELME N/A
  • BEAM 2020
  • Fundamental
  • Price
  • ELME $17.13
  • BEAM $20.60
  • Analyst Decision
  • ELME Hold
  • BEAM Strong Buy
  • Analyst Count
  • ELME 7
  • BEAM 10
  • Target Price
  • ELME $15.50
  • BEAM $48.56
  • AVG Volume (30 Days)
  • ELME 924.7K
  • BEAM 2.8M
  • Earning Date
  • ELME 11-03-2025
  • BEAM 11-04-2025
  • Dividend Yield
  • ELME 4.22%
  • BEAM N/A
  • EPS Growth
  • ELME N/A
  • BEAM N/A
  • EPS
  • ELME N/A
  • BEAM N/A
  • Revenue
  • ELME $245,911,000.00
  • BEAM $60,272,000.00
  • Revenue This Year
  • ELME N/A
  • BEAM N/A
  • Revenue Next Year
  • ELME $6.20
  • BEAM $17.95
  • P/E Ratio
  • ELME N/A
  • BEAM N/A
  • Revenue Growth
  • ELME 4.59
  • BEAM N/A
  • 52 Week Low
  • ELME $13.95
  • BEAM $13.53
  • 52 Week High
  • ELME $18.49
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • ELME 61.44
  • BEAM 60.10
  • Support Level
  • ELME $16.84
  • BEAM $19.57
  • Resistance Level
  • ELME $17.25
  • BEAM $21.59
  • Average True Range (ATR)
  • ELME 0.18
  • BEAM 1.23
  • MACD
  • ELME -0.02
  • BEAM 0.50
  • Stochastic Oscillator
  • ELME 69.05
  • BEAM 82.23

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: